Xeris Biopharma (XERS) Projected to Release Earnings on Thursday

Key Points

• Xeris Biopharma is expected to report Q3 2026 results on November 5 before the market opens, with analysts forecasting $0.0317 in earnings per share and $101.68 million in revenue.
• The company previously missed quarterly EPS estimates, reporting a $0.18 loss per share, though revenue exceeded expectations at $92.10 million. Analysts project $0.07 EPS for the current fiscal year and $0.30 for the next.
• XERS recently traded at $10.64, near its 12-month high, while analyst sentiment remains mixed: the consensus rating is “Hold” with an average price target of $13.20; insiders have sold nearly 135,000 shares over the past 90 days.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) is expected to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of $0.0317 per share and revenue of $101.68 million for the quarter. Parties may visit the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of $0.01 by ($0.19). The company had revenue of $92.10 million for the quarter, compared to analyst estimates of $90.12 million. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. On average, analysts expect Xeris Biopharma to post $0.07 EPS for the current fiscal year and $0.30 EPS for the next fiscal year.

Xeris Biopharma Trading Up 1.8%

XERS opened at $10.64 on Thursday. The stock has a market capitalization of $1.94 billion, a P/E ratio of -96.73 and a beta of 0.53. Xeris Biopharma has a 12 month low of $5.25 and a 12 month high of $11.41. The firm's fifty day simple moving average is $9.23 and its 200 day simple moving average is $7.48. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 17.00.

Insiders Place Their Bets

In other Xeris Biopharma news, insider Steven Pieper sold 5,000 shares of Xeris Biopharma stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $9.41, for a total value of $47,050.00. Following the completion of the transaction, the insider directly owned 1,351,053 shares of the company's stock, valued at $12,713,408.73. The trade was a 0.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin McCulloch sold 25,000 shares of Xeris Biopharma stock in a transaction on Monday, September 28th. The shares were sold at an average price of $10.00, for a total value of $250,000.00. Following the completion of the transaction, the insider directly owned 1,614,208 shares of the company's stock, valued at $16,142,080. This represents a 1.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 134,998 shares of company stock worth $1,202,666 in the last 90 days. Company insiders own 4.35% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Leerink Partners upped their price objective on Xeris Biopharma from $12.00 to $16.00 and gave the stock an "outperform" rating in a research report on Thursday, September 10th. Wall Street Zen raised Xeris Biopharma from a "hold" rating to a "buy" rating in a research report on Saturday, September 19th. Weiss Ratings lowered shares of Xeris Biopharma from a "hold (c-)" rating to a "sell (d-)" rating in a research note on Tuesday, August 11th. Finally, Barclays lifted their price target on Xeris Biopharma from $12.00 to $14.00 and gave the stock an "overweight" rating in a report on Tuesday, October 6th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $13.20.

About Xeris Biopharma

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris' commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing's syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.